THRX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 46.70%

Insider Buying (Last 12 Months): $3,542,792.60

Insider Selling (Last 12 Months): $0.00

Theseus Pharmaceuticals Insider Trading History Chart

Theseus Pharmaceuticals Share Price & Price History

^$3.78

▲ +0.01 (0.27%)

As of 12/8/2023 01:00 AM ET

Days: 30 | 90 | 365

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

Invest in Autonomix today.

Theseus Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/17/2023	Carl L. Gordon	Director	Buy	479,932	$3.05	$1,463,792.60	17,063,000
7/17/2023	Foresite Capital Management V,	Major Shareholder	Buy	700,000	$2.97	$2,079,000.00	4,108,796
11/30/2022	Bradford D. Dahms	CFO	Buy	1,502	$6.66	$10,003.32	6,142
11/7/2022	Carl L. Gordon	Director	Buy	192,000	$5.21	$1,000,320.00	16,734,518
1/21/2022	Carl L. Gordon	Director	Buy	111,896	$9.97	$1,115,603.12
1/19/2022	Carl L. Gordon	Director	Buy	11,521	$9.97	$114,864.37
1/13/2022	Carl L. Gordon	Director	Buy	17,320	$9.43	$163,327.60
1/11/2022	Carl L. Gordon	Director	Buy	8,500	$10.51	$89,335.00
12/21/2021	Bradford D. Dahms	CFO	Buy	1,970	$10.15	$19,995.50
12/21/2021	Timothy P. Clackson	CEO	Buy	2,600	$9.76	$25,376.00

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for Theseus Pharmaceuticals (NASDAQ:THRX)

91.05% of Theseus Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Theseus Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/30/2023	American Century Companies Inc.	10,514	$28K	0.0%	N/A	0.024%
11/21/2023	Walleye Capital LLC	31,998	$86K	0.0%	N/A	0.073%
11/15/2023	The Manufacturers Life Insurance Company	79,751	$0.22M	0.0%	-9.3%	0.183%
11/15/2023	GSA Capital Partners LLP	36,587	$98K	0.0%	N/A	0.084%
11/15/2023	Laurion Capital Management LP	171,157	$0.46M	0.0%	-4.7%	0.393%
11/15/2023	Affinity Asset Advisors LLC	400,726	$1.08M	0.3%	+66.8%	0.919%
11/14/2023	Lynx1 Capital Management LP	702,415	$1.89M	1.2%	-7.2%	1.611%
11/13/2023	Northern Trust Corp	157,325	$0.42M	0.0%	-4.1%	0.361%
11/13/2023	Foresite Capital Management V LLC	4,108,796	$11.05M	17.6%	+14.6%	9.424%
11/13/2023	Acadian Asset Management LLC	259,470	$0.70M	0.0%	N/A	0.595%
11/9/2023	UBS Group AG	10,750	$29K	0.0%	+154.1%	0.025%
11/8/2023	Forefront Analytics LLC	17,672	$48K	0.0%	N/A	0.041%
10/27/2023	TD Asset Management Inc	213,896	$0.58M	0.0%	+100.0%	0.491%
10/20/2023	Denali Advisors LLC	127,900	$0.34M	0.1%	+675.2%	0.293%
10/18/2023	Exchange Traded Concepts LLC	36,210	$97K	0.0%	+144.8%	0.083%
8/21/2023	Affinity Asset Advisors LLC	240,244	$2.24M	0.8%	+144.6%	0.551%
8/16/2023	Nuveen Asset Management LLC	82,478	$0.77M	0.0%	+277.5%	0.189%
8/15/2023	Alliancebernstein L.P.	218,478	$2.04M	0.0%	+41.6%	0.501%
8/15/2023	Wells Fargo & Company MN	7,709	$72K	0.0%	+156.4%	0.018%
8/15/2023	Goldman Sachs Group Inc.	28,941	$0.27M	0.0%	N/A	0.066%
8/15/2023	HighVista Strategies LLC	136,719	$1.28M	0.6%	N/A	0.314%
8/15/2023	Citadel Advisors LLC	604,550	$5.64M	0.0%	+24.8%	1.387%
8/14/2023	State Street Corp	367,516	$3.43M	0.0%	+23.8%	0.843%
8/14/2023	Nuveen Asset Management LLC	82,478	$0.77M	0.0%	+277.5%	0.189%
8/14/2023	Driehaus Capital Management LLC	232,693	$2.17M	0.0%	+2.9%	0.534%
8/11/2023	Renaissance Technologies LLC	41,200	$0.38M	0.0%	-68.5%	0.095%
8/11/2023	BlackRock Inc.	1,333,868	$12.45M	0.0%	+51.0%	3.061%
8/11/2023	The Manufacturers Life Insurance Company	87,881	$0.82M	0.0%	+10.2%	0.202%
8/11/2023	Geode Capital Management LLC	421,522	$3.93M	0.0%	+28.6%	0.967%
8/11/2023	Northern Trust Corp	164,115	$1.53M	0.0%	+23.0%	0.377%
8/10/2023	Charles Schwab Investment Management Inc.	56,203	$0.52M	0.0%	+24.6%	0.129%
8/10/2023	Citigroup Inc.	6,029	$56K	0.0%	N/A	0.014%
8/9/2023	Dimensional Fund Advisors LP	78,993	$0.74M	0.0%	N/A	0.181%
8/8/2023	Candriam S.C.A.	270,015	$2.52M	0.0%	-16.6%	0.620%
8/7/2023	Principal Financial Group Inc.	10,679	$100K	0.0%	N/A	0.025%
8/3/2023	Barclays PLC	8,365	$77K	0.0%	-35.6%	0.019%
8/3/2023	Bank of New York Mellon Corp	59,553	$0.56M	0.0%	+14.8%	0.137%
8/2/2023	Bank of Montreal Can	277,074	$2.80M	0.0%	N/A	0.636%
7/20/2023	Exchange Traded Concepts LLC	14,791	$0.14M	0.0%	N/A	0.034%
7/18/2023	Denali Advisors LLC	16,500	$0.15M	0.1%	N/A	0.038%
5/18/2023	JPMorgan Chase & Co.	13,037	$0.12M	0.0%	+35.3%	0.030%
5/16/2023	Hudson Bay Capital Management LP	35,000	$0.31M	0.0%	N/A	0.080%
5/16/2023	State Street Corp	296,864	$2.64M	0.0%	+9.3%	0.681%
5/16/2023	Fairmount Funds Management LLC	1,865,671	$16.57M	2.8%	N/A	4.281%
5/16/2023	Geode Capital Management LLC	327,870	$2.91M	0.0%	+9.4%	0.752%
5/16/2023	Altium Capital Management LP	112,614	$1M	0.6%	N/A	0.258%
5/16/2023	Boxer Capital LLC	350,000	$3.11M	0.2%	-15.7%	0.803%
5/15/2023	Schonfeld Strategic Advisors LLC	78,369	$0.70M	0.0%	N/A	0.180%
5/15/2023	Cubist Systematic Strategies LLC	18,081	$0.16M	0.0%	N/A	0.041%
5/15/2023	Affinity Asset Advisors LLC	98,221	$0.87M	0.3%	N/A	0.225%
5/15/2023	Two Sigma Advisers LP	28,400	$0.25M	0.0%	N/A	0.065%
5/15/2023	Two Sigma Investments LP	74,089	$0.66M	0.0%	+331.4%	0.170%
5/15/2023	Deutsche Bank AG	10,644	$95K	0.0%	+11.8%	0.024%
5/15/2023	Price T Rowe Associates Inc. MD	1,325,565	$11.77M	0.0%	+0.9%	3.042%
5/12/2023	Renaissance Technologies LLC	130,600	$1.16M	0.0%	+594.7%	0.300%
5/12/2023	Candriam S.C.A.	323,816	$2.65M	0.0%	N/A	0.743%
5/12/2023	BlackRock Inc.	883,462	$7.85M	0.0%	+2.1%	2.027%
5/12/2023	Bank of America Corp DE	179,202	$1.59M	0.0%	+1,125.7%	0.411%
5/12/2023	UBS Group AG	6,851	$61K	0.0%	+47.5%	0.016%
5/12/2023	Wellington Management Group LLP	111,612	$0.99M	0.0%	N/A	0.256%
5/12/2023	Charles Schwab Investment Management Inc.	45,111	$0.40M	0.0%	+4.1%	0.104%
5/11/2023	FMR LLC	1,113,662	$9.89M	0.0%	-55.4%	2.555%
5/10/2023	Tekla Capital Management LLC	75,000	$0.67M	0.0%	-25.0%	0.172%
5/9/2023	Bank of New York Mellon Corp	51,862	$0.46M	0.0%	+19.2%	0.119%
5/4/2023	Barclays PLC	12,993	$0.12M	0.0%	+45.9%	0.030%
5/3/2023	Jump Financial LLC	15,859	$0.14M	0.0%	N/A	0.036%
2/15/2023	Morgan Stanley	11,478	$57K	0.0%	+31.1%	0.030%
2/14/2023	Boxer Capital LLC	415,000	$2.07M	0.1%	-53.5%	1.072%
2/14/2023	Price T Rowe Associates Inc. MD	1,313,908	$6.54M	0.0%	-4.9%	3.394%
2/14/2023	Two Sigma Investments LP	17,175	$86K	0.0%	N/A	0.044%
2/13/2023	Foresite Capital Management V LLC	3,585,346	$17.86M	13.9%	+7.5%	9.262%
2/13/2023	Barclays PLC	8,904	$44K	0.0%	+76.0%	0.023%
2/13/2023	Renaissance Technologies LLC	18,800	$94K	0.0%	N/A	0.049%
2/13/2023	Geode Capital Management LLC	299,606	$1.49M	0.0%	+4.2%	0.774%
2/10/2023	Opaleye Management Inc.	535,000	$2.66M	0.9%	+142.5%	1.382%
2/10/2023	Bank of America Corp DE	14,620	$73K	0.0%	+148.0%	0.038%
2/3/2023	Frazier Life Sciences Management L.P.	1,398,194	$6.96M	0.4%	N/A	3.612%
12/8/2022	Bank of New York Mellon Corp	43,144	$0.25M	0.0%	+11.2%	0.111%
11/16/2022	BNP Paribas Arbitrage SNC	15,310	$89K	0.0%	N/A	0.040%
11/15/2022	State Street Corp	248,281	$1.44M	0.0%	+6.2%	0.641%
11/15/2022	Vanguard Group Inc.	625,943	$3.63M	0.0%	-0.5%	1.617%
11/15/2022	Price T Rowe Associates Inc. MD	1,381,489	$8.01M	0.0%	-0.3%	3.569%
11/15/2022	Farallon Capital Management LLC	223,149	$1.29M	0.0%	-45.5%	0.576%
11/15/2022	Bank of New York Mellon Corp	43,144	$0.25M	0.0%	+11.2%	0.111%
11/15/2022	BlackRock Inc.	775,590	$4.50M	0.0%	+12.8%	2.004%
11/14/2022	Nuveen Asset Management LLC	36,636	$0.21M	0.0%	+15.5%	0.095%
11/14/2022	Forefront Analytics LLC	13,065	$74K	0.0%	N/A	0.034%
11/10/2022	Tower Research Capital LLC TRC	4,420	$26K	0.0%	+66.0%	0.011%
8/19/2022	Walleye Capital LLC	31,719	$0.18M	0.0%	N/A	0.082%
8/16/2022	Woodline Partners LP	211,684	$1.17M	0.0%	-15.3%	0.547%
8/16/2022	Price T Rowe Associates Inc. MD	1,385,283	$7.66M	0.0%	-3.6%	3.579%
8/16/2022	DAFNA Capital Management LLC	81,899	$0.45M	0.1%	+2.2%	0.212%
8/15/2022	State Street Corp	233,893	$1.29M	0.0%	+28.0%	0.604%
8/15/2022	Opaleye Management Inc.	32,300	$0.18M	0.1%	N/A	0.083%
8/13/2022	American International Group Inc.	7,952	$44K	0.0%	+39.2%	0.021%
8/12/2022	Northern Trust Corp	128,060	$0.71M	0.0%	+31.8%	0.331%
8/12/2022	Ensign Peak Advisors Inc	142,598	$0.79M	0.0%	-43.0%	0.368%
8/12/2022	FMR LLC	5,183,363	$28.66M	0.0%	-6.7%	13.394%
8/12/2022	Rhumbline Advisers	23,405	$0.13M	0.0%	N/A	0.060%
8/11/2022	JPMorgan Chase & Co.	9,084	$50K	0.0%	+68.3%	0.023%

Data available starting January 2016

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Today's Range

Now: $3.78

$3.73

$3.82

50 Day Range

MA: $2.83

$2.12

$3.86

52 Week Range

Now: $3.78

$2.05

$14.77

Volume

153,705 shs

Average Volume

1,654,882 shs

Market Capitalization

$167.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.05

Who are the company insiders with the largest holdings of Theseus Pharmaceuticals?: Theseus Pharmaceuticals' top insider shareholders include:
Carl L Gordon (Director)
Foresite Capital Management V, (Major Shareholder)
Bradford D Dahms (CFO)
Timothy P Clackson (CEO)
Learn More about top insider investors at Theseus Pharmaceuticals.
Who are the major institutional investors of Theseus Pharmaceuticals?: Theseus Pharmaceuticals' top institutional shareholders include:
Foresite Capital Management V LLC — 9.42%
Lynx1 Capital Management LP — 1.61%
Affinity Asset Advisors LLC — 0.92%
Acadian Asset Management LLC — 0.60%
TD Asset Management Inc — 0.49%
Laurion Capital Management LP — 0.39%
Learn More about top institutional investors of Theseus Pharmaceuticals stock.
Which major investors are selling Theseus Pharmaceuticals stock?: Within the previous quarter, THRX stock was sold by these institutional investors:
Lynx1 Capital Management LP
Laurion Capital Management LP
The Manufacturers Life Insurance Company
Northern Trust Corp
Which major investors are buying Theseus Pharmaceuticals stock?: During the last quarter, THRX stock was purchased by institutional investors including:
Foresite Capital Management V LLC
Acadian Asset Management LLC
Affinity Asset Advisors LLC
Denali Advisors LLC
TD Asset Management Inc
GSA Capital Partners LLP
Walleye Capital LLC
Exchange Traded Concepts LLC
During the last year, these company insiders have bought Theseus Pharmaceuticals stock:
Carl L Gordon (Director)
Foresite Capital Management V, (Major Shareholder)
Bradford D Dahms (CFO)
Timothy P Clackson (CEO)
Learn More investors buying Theseus Pharmaceuticals stock.